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a b s t r a c t 
Background: Pathogenesis of progressive liver fibrosis in biliary atresia after successful portoenterostomy 
remains unclear. We related hepatic expression of transforming growth factor beta (TGF- β) superfamily 
cytokines to histologic liver injury after successful portoenterostomy. 
Methods: Enrolled in our study were 28 patients with biliary atresia who had liver biopsies obtained 
during and after successful portoenterostomy, which normalized serum bilirubin ( < 20 μmol/l). Biopsies 
were evaluated for cholestasis, inflammation, ductal reaction, and fibrosis and were stained immunohis- 
tochemically for transforming growth factor beta 1, transforming growth factor beta 2, connective tissue 
growth factor, and decorin. Respective gene expression ( TGFB1, TGFB2, TGFB3, CTGF, DCN ) was analyzed 
at follow-up using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results were 
compared with fibrotic and healthy control livers. 
Results: After median follow-up of 3.0 years, histologic cholestasis resolved, whereas fibrosis had pro- 
gressed only in isolated biliary atresia. Liver protein expression of transforming growth factor beta 1 and 
connective tissue growth factor ( P < .001 for both), but not that of transforming growth factor beta 2 or 
decorin, decreased after successful portoenterostomy, although expression of all four cytokines remained 
elevated. In accordance with postportoenterostomy changes in protein expression, follow-up ribonucleic 
acid expression of TGFB2 and DCN, but not that of TGFB1 and CTGF, was upregulated when compared 
with the controls. Both protein and gene expression of transforming growth factor beta 1 and protein 
expression of transforming growth factor beta 2, connective tissue growth factor and decorin correlated 
with METAVIR fibrosis stage. Syndromic patients ( n = 12) showed milder fibrosis and lower transforming 
growth factor beta 1 expression than patients with isolated biliary atresia. 
Conclusion: These findings support a central role of transforming growth factor beta superfamily in me- 
diating continuing liver fibrogenesis after successful portoenterostomy. Transforming growth factor beta 
pathway cytokines responded divergently to clearance of jaundice, which was reflected by differential 
progression of fibrosis between syndromic and isolated patients. 
















Biliary atresia (BA) is an obliterative fibroinflammatory cholan-
iopathy of infancy, with an incidence of 1 in 18,0 0 0–20,0 0 0 live
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039-6060/© 2018 Elsevier Inc. All rights reserved. nd environmental factors, such as viral infection, play a part in its
ultifactorial etiology. 1,3,4 Up to 20%–30% of patients have asso-
iated anomalies and presumably different pathogenesis from the
solated disease. 1 , 4–6 Liver histology at diagnosis is characterized
y cholestasis, ductular proliferation, inflammation, and fibrosis. 3 
espite successful restoration of bile flow and normalization of
erum bilirubin by portoenterostomy (PE), the great majority of
atients develop progressing liver fibrosis and liver failure. 2,3 Al-
hough BA is the leading indication for pediatric liver transplanta-
ion (LTx) worldwide, 2 the molecular mechanisms of liver fibrosis
4 fter PE remain unclear. 









































































































The transforming growth factor beta (TGF- β) superfamily
consists of several cytokines that play important roles in the
regulation of hepatic fibrogenesis, growth, development, and
immunity. 7–9 TGF- β is a potent activator of portal fibroblasts
and hepatic stellate cells into α-smooth muscle acting ( α-SMA)
expressing myofibroblasts, which mediate liver fibrogenesis by
producing extracellular matrix proteins. 10,11 Previous studies in
BA have found an increased hepatic messenger ribonucleic acid
(mRNA) and a protein expression of TGF- β at the time of diagnosis
and in explants with advanced stages of the disease after develop-
ment of liver failure. 12–22 Connective tissue growth factor (CTGF)
synergizes the profibrotic actions of TGF- β , and its expression has
been found to increase in BA. 23–25 Decorin is a proteoglycan in-
volved in the maturation of collagen and possibly in attenuation of
TGF- β1 activity in hepatic fibrogenesis. 26 
We investigated how the expression of TGF- β superfamily
members evolves and relates with histologic liver injury in BA pa-
tients after normalization of serum bilirubin by successful PE be-
fore development of clinical and biochemical signs of advanced
liver dysfunction. This knowledge is essential for the development
of novel management strategies to delay or prevent the progres-
sion of liver fibrosis after successful PE. 
Materials and Methods 
Patients and ethics 
Of 51 BA patients operated in Helsinki University Hospital (Fin-
land) between 1991 and 2013, 30 patients (59%) cleared their
jaundice after PE, and 28 of them (93%) were enrolled. They
underwent liver biopsy at PE. An ultrasound-guided core-needle
liver biopsy was obtained during routine follow-up, including en-
doscopic variceal surveillance under anesthesia, abdominal ultra-
sound examination, and blood sampling. 27 Follow-up liver biop-
sies were part of the routine follow-up protocol not warranted
by patients’ clinical status. 28 Splenomegaly and portal hyper-
tension were defined as described elsewhere. 27 Associated con-
genital anomalies were recorded from medical records and BA
splenic malformation (BASM) was defined as having polysplenia or
asplenia. 29 
Study protocol was approved by Ethics Committee of the Hos-
pital District of Helsinki and Uusimaa (number 345/13/03/03/2008)
and ethical guidelines of the 1975 Declaration of Helsinki were fol-
lowed. Informed consent was obtained from all legal guardians of
participating children and from adults. 
Controls 
Healthy nonfibrotic control liver biopsies were obtained from
19 pediatric donor livers (median age 14.2 years [interquartile
range 8.0–16.2 years]) and from 10 children (age 11.4 years [7.8–
14.8 years]) undergoing cholecystectomy for cholecystolithiasis (re-
search protocol 434/13/03/03/2008). Fibrotic control liver tissue
was obtained from 11 patients with intestinal failure (age 4.7 years
[3.5–9.7 years]). Control blood samples were obtained from 47 gen-
erally healthy ambulatory-surgery patients (age 6.5 years [4.2–12.6
years]) with no liver disease. 
Liver biopsies and immunohistochemistry 
In total, 24 liver biopsies obtained at PE and 28 at follow-
up were available for analyses. After fixation in formalin, embed-
ding in paraffin, slicing, and staining, liver biopsies were analyzed
semiquantitatively by two experienced pediatric pathologists for
METAVIR fibrosis stage (0–4), portal inflammation (0–3), and in-
tracanalicular cholestasis (0–3). 27 Immunohistologic studies were performed with antibodies for
GF- β1 (clone TGFB17; Leica Novocastra, Leica Biosystems, Nuss-
och, Germany), TGF- β2 (clone MGC116892; Abnova Corporation,
aipei City, Taiwan), CTGF (clone L-20; Santa Cruz Biotechnology
nc, Dallas, TX, USA), and decorin (clone NBP1-84970, Novus Bi-
logicals, LLC, Littleton, CO, USA). Dilutions were 1:50, 1:10 0 0,
:400, and 1:750, respectively. Blinded to clinical data, primary au-
hor (A.K.) performed semiquantitative immunohistologic gradings
ith a Leica DM RXA microscope (Leica Microsystems GmbH, Wet-
lar, Germany), as follows: 
• TGF- β1 and CTGF: 0 = negative, 1 = mild, 2 = moderate, and
3 = strong staining 
• TGF- β2: 0 = negative, 1 = mild, and 2 = moderate staining 
• decorin: 0 = slight expression at portal areas, 1 = expanded
expression at portal areas, 2 = with portal-to-portal septaes,
3 = with portal-to-central septaes, 4 = expanded nodular ex-
pression (cirrhosis) 
Staining of bile duct epithelial cells (BECs) was graded dichoto-
ously for TGF- β2. The expression of TGF- β1 and CTGF were also
valuated for localization (most staining in fibrotic = 0, parenchy-
al = 1, or both areas = 2). The periportal staining pattern was
raded dichotomously for TGF- β1, TGF- β2, and CTGF. 
Cytokeratin-7 (CK-7) expression was used to visualize ductal
eaction because it stains proliferating bile ductules, metaplas-
ic hepatocyte-cholangiocyte intermediate cells, and bile ducts. 30,31 
mmunostaining for CK-7 was performed using SP52 monoclonal
ntibody and ultra View Universal DAB Detection KIT (Ventana,
uscon, AZ, USA). Immunostaining for α-SMA, a marker of acti-
ated myofibroblasts, was performed as described in detail else-
here. 32 The proportion of the antibody-positive area to the entire
iopsy surface area (area fraction) was calculated for CK-7 and α-
MA, using ImageJ Image Analysis Software (SciJava Common open
ource software; Rasband, WS, ImageJ, US National Institutes of
ealth, Bethesda, MD, USA; http://imagej.nih.gov/ij/ ; 1997–2014). 
NA expression analyses 
RNA expression was analyzed from 24 BA patients with BA who
ad a liver RNA specimen available ( Table 1 ). Liver tissue speci-
ens were embedded in RNAlater-solution (Ambion, Life Technolo-
ies, Thermo Fischer Scientific Inc, Waltham, MA, USA) and frozen
NA was extracted with RNeasy Mini Kit (QIAGEN, Frederick, MD,
SA). RNA integrity was determined spectrophotometrically, and
he expression was analyzed in triplicate by quantitative real-time
olymerase chain reaction using Human Fibrosis RT 2 Profiler PCR
rray (QIAGEN SABiosciences, Frederick, MD, USA) on an ABI 7700
equence Detection System (Perkin-Elmer Lifer Sciences, Boston,
A, USA), according to the manufacturer’s directions. Quantifica-
ion of target gene mRNA expression was performed using the
Ct method and expressed after normalization to housekeeping
enes ( B2M, HPRT1, RPL13A, GAPDH, ACTB ) and relative to control
ubjects. 
nalyses of serum TGF- β2 and decorin 
The serum concentrations of TGF- β2 and decorin were deter-
ined using commercially available enzyme-linked immune sor-
ent assay (ELISA) kits by Biovendor R&D (Bratislava, Slovakia).
he analyses for human-TGF- β2 and human decorin were car-
ied out according to the manufacturer’s protocol. The interas-
ay coefficient of variations (CV%) for TGF- β2 and decorin were
0.0% and 5.8 ng/mL, and detection limits were 6.6 and 56 pg/mL,
espectively. 
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Table 1 
Hepatic gene expression of transforming growth factor-beta (TGF- β) superfamily in biliary atresia patients 
after a median follow-up of 3.0 years in relation to controls 
Gene Biliary atresia at follow-up Intestinal failure controls Cholelithiasis controls P value 
n = 24 n = 11 n = 10 
TGF- β
TGFB1 1.02 (0.89–1.36) 0.86 (0.65–0.96) 1.04 (0.76–1.20) .051 
TGFb2 3.73 (3.01–8.16) ∗ , † 0.88 (0.67–1.23) 1.00 (0.68–1.44) < .001 
TGFB3 2.04 (1.49–2.40) ∗ , † 1.18 (0.78–1.37) 1.01 (0.91–1.32) < .001 
Receptors 
TGFBR1 1.55 (1.30–2.08) ∗ , † 0.69 (0.59–0.84) 1.04 (0.72–1.37) < .001 
TGFBR2 0.98 (0.90–1.26) 0.84 (0.80–1.01) 0.96 (0.93–1.15) .107 
Signaling pathway 
SMAD2 1.42 (1.14–1.73) ∗ , † 0.80 (0.72–0.96) 0.92 (0.72–1.46) < .001 
SMAD6 0.57 (0.40–0.93) † 0.52 (0.36–0.68) ‡ 1.00 (0.79–1.27) .001 
Interactors and mediators 
CTGF 1.06 (0.66–1.64) ∗ 0.48 (0.44–0.79) 0.90 (0.60–1.46) .025 
DCN 1.43 (1.21–2.00) ∗ , † 1.07 (0.87–1.17) 0.98 (0.92–1.11) < .001 
∗ P < .018 compared with fibrotic intestinal failure controls. 
† P < .02 compared with nonfibrotic cholelithiasis controls. 
‡ P < .001 between intestinal failure controls and cholelithiasis controls. Note: Data are median (interquar- 
tile range). The RNA expression is expressed after normalization to housekeeping genes as fold change relative 
to cholelithiasis control subjects. Significance was evaluated for multiple groups, using the Kruskall-Wallis H 






































Histology and immunohistochemistry at portoenterostomy (PE) and after a median 
follow-up of 3.0 years 
All patients n Syndromic BA n Isolated BA n 
Metavir stage (0–4) 
PE 2 (2–3) 24 2 (2–3) 9 2 (2–3) 15 
Follow-up 2 (1–4) 28 2 (1–2) 12 3 (2–4) 16 
P value P = .170 P = .579 P = .026 
Portal inflammation (0–3) 
PE 2 (2–3) 24 2 (2–3) 9 2 (2–3) 15 
Follow-up 1 (0–1) 28 0 (0–1) 12 1 (1–2) 16 
P value P < .001 P = .01 P = .002 
cholestasis (0–3) 
PE 2 (1–3) 24 2 (1–3) 9 2 (1–3) 15 
Follow-up 0 (0–0) 28 0 (0–0) 12 0 (0–0) 16 
P value P < .001 P = .007 P = .001 
Ductal reaction (%) ∗
PE 5.0 (3.3–7.0) 20 5.3 (3.4–7.0) 8 4.3 (2.9–7.8) 12 
Follow-up 2.4 (1.8–4.9) 27 1.9 (1.5–4.1) 11 3.1 (1.8–8.6) 16 
P value P = .227 P = .028 P = .937 
TGF- β1, grade (0–3) 
PE 2 (2–3) 22 2 (2–2) 9 2 (2–3) 13 
Follow-up 1 (0–1) 27 0 (0–1) 11 1 (0–1) 16 
P value P < .001 P = .014 P = .003 
TGF- β2, grade (0–2) 
PE 1 (1–1) 23 1 (1–1) 8 1 (1–1) 15 
Follow-up 1 (0–1) 28 0.5 (0–1) 12 1 (0–1) 16 
P value P = .09 P = .414 P = .132 
CTGF, grade (0–4) 
PE 2 (2–3) 23 2.5 (2–3) 8 2 (2–2) 15 
Follow-up 1 (0–1) 27 1 (0–1) 12 1 (0–1) 15 
P value P < .001 P = .019 P = .003 
Decorin, grade (0–4) 
PE 2 (2–3) 17 2.5 (2–3) 6 2.5 (2–4) 11 
Follow-up 2 (1.5–2.5) 25 2 (1–2) 11 2 (2–3) 14 
P value P = .409 P = .279 P = .891 
TGF- β , transfroming growth factor-beta; CTGF , connective tissue growth factor. 
∗ Ductal reaction was analyzed using cytokeratin-7 immunostaining (area frac- 
tion). 
Note: Data are median (interquartile range). Significance was evaluated using 





s  tatistical analyses 
SPSS software v 22.0 for Windows (IBM Corp, Armonk, NY,
SA) was used for statistical analyses. Data are medians (interquar-
ile range [IQR]), unless otherwise stated. Kruskall-Wallis test was
sed for multiple comparisons. Pairwise comparisons of continu-
us variables were performed using the Wilcoxon signed rank test
r the Mann-Whitney U test, where appropriate, and the Fisher
xact test for dichotomous variables. Correlations were calculated
ith the Spearman rank correlation. A P value below .05 was con-
idered statistically significant. 
esults 
atient characteristics 
Median patient (50% males) age at PE was 61 (interquartile
ange 40–84) days and 3.0 (2.1–6.7) years at follow-up. A total of
6 patients (57%) had isolated BA, and 12 patients (43%) had asso-
iated congenital anomalies (syndromic BA), including splenic mal-
ormations (BASM) in 8 patients (29%). At follow-up, splenomegaly
as recorded in 9 patients (32%), and 14 patients (50%) had clinical
igns of portal hypertension. After PE, bilirubin level had decreased
rom 159 (116–204) μmol/L to 10 (4–17) μmol/L, conjugated biliru-
in from 115 (83–159) to 4 (2–8) μmol/L (both p < 0.001), and ala-
ine aminotransferase from 87 (42–164) U/L to 45 (24–94) U/L,
 P = .012). 
volution of histology and immunohistochemistry after PE 
After successful PE, histologic liver fibrosis progressed in iso-
ated BA patients, but remained unchanged in syndromic BA,
nd cholestasis disappeared and portal inflammation reduced in
oth groups ( Table 2 ). CK-7 expression, which reflects the exten-
ion of ductal reaction, decreased significantly after PE in syn-
romic patients ( Table 2 ). The CK-7 area fraction correlated with
ETAVIR fibrosis stage both at PE (r = 0.611, P = .004) and at
ollow-up (r = 0.467, P = .014). METAVIR fibrosis stage was unre-
ated to follow-up age (r = 0.035, P = .859). 
The hepatic expression of TGF- β1 and CTGF, but not that
f TGF- β2 or decorin, significantly decreased after successful PE
 Table 2 , Figs 1 and 2 ). However, the protein expression of all fourytokines remained significantly higher when compared with non-
brotic control liver biopsies (0 [0–0], P < .003 for all, see Table
 ). TGF- β1 was expressed around lobular hepatocytes and in fi-
rotic areas. The CTGF staining was perceived mainly as spindle-
haped periportal cells, but especially at follow-up also in lobu-
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Fig 1. Hepaticv transforming growth factor beta 1 (TGF- β1) protein expression reduced significantly after portoenterostomy (PE). ( A ) PE of a patient 105 days old, hepatic 
TGF- β1 protein expression was grade 3 and seen both in fibrotic ( asterisk) and parenchymal areas, with METAVIR stage and portal inflammation were grade 2 and intra- 
canalicular cholestasis grade 3 ( × 200). ( B ) Liver biopsy at 2.4 years of the same patient shows reduced TGF- β1 protein expression and resolved cholestasis to grade 0, with 
METAVIR stage and portal inflammation grade 1 ( × 200; portal area [ asterisk ]). ( C ) Hepatic TGF- β1 expression reduced after portoenterostomy ( n = 27). Box plots display 
median ( bold transverse line ), interquartile range ( rectangle ), and range. Significance was evaluated using the Wilcoxon sign rank test. 
Fig 2. Hepatic transforming growth factor beta 2 (TGF- β2) protein expression persisted after portoenterostomy (PE). ( A ) PE of a patient 104 days old, hepatic TGF- β2 protein 
expression was grade 2 and expressed around lobular hepatocytes, METAVIR stage was 4, portal inflammation grade 2, and intracanalicular cholestasis grade 3. The fibrotic 
area is indicated by an asterisk ( × 200). ( B ) Liver biopsy of the same patient 18.9 years later shows reduced TGF- β2 protein expression and portal inflammation to grade 1, 
resolved cholestasis to grade 0, with METAVIR stage 4. TGF- β2 expression concentrated in periportal areas. The fibrotic area is indicated by an asterisk ( × 200). ( C ) Hepatic 
TGF- β2 persisted after portoenterostomy ( n = 28). Box plots display the median ( bold transverse line ), interquartile range ( rectangle ), and range. Significance was evaluated 


































lar hepatocytes. The periportal CTGF positivity was more frequent
at PE (74%) than at follow-up (4%, P = .003). No such change was
observed for periportal TGF- β1 (45% versus 20%, P = .50). TGF-
β1 and CTFG staining concentrated more to the fibrotic areas
at follow-up than at PE (0 [0–0] versus 2 [0–2], P = .025 and 0
[0–2] versus 2 [2–2]), P = .005). TGF- β2 immunostaining was de-
tected mainly around lobular hepatocytes both during and after PE
( Table 2 and Fig 2 ). Frequency of periportal TGF- β2 expression was
significantly higher at follow-up (50%) than at PE (14%, P = .039;
Fig 2 ). At follow-up in 25% of samples, BECs expressed TGF- β2,
which was not observed at PE (0%, P = .125). Expression of decorin
was observed in portal and fibrotic areas similarly at PE and
follow-up. 
RNA expression of TGF- β-superfamily cytokines in BA patients 
compared with fibrotic and nonfibrotic controls 
As presented in Table 1 , the follow-up RNA expression of TGFB2,
TGFB3 , and DCN —but not that of TGFB1 and CTGF —was upregu-
lated in BA patients compared with both control groups. Controls
with intestinal failure had comparable liver METAVIR fibrosis stage2 [2–2], P = .370) versus BA, and nonfibrotic controls were oper-
ted for cholelithiasis. The RNA expression of TGFBR1 and SMAD2
as also upregulated compared with both control groups. In con-
rast, the RNA expression of SMAD6 was significantly downregu-
ated compared with nonfibrotic controls. 
GF- β1 expression correlated with liver fibrosis 
In follow-up specimens both protein and RNA expression
f TGF- β1 correlated positively with the METAVIR fibrosis
tage ( Fig 3 ). In addition, TGF- β2 ( Fig 3 ), CTGF (r = 0.478,
 = .012) and decorin (r = 0.825, P < .001) protein expres-
ion associated with fibrosis ( Fig 3 ). At follow-up, the exten-
ion of CK-7 staining marking ductal reaction correlated with
he decorin (r = 0.542, P = .006) and CTGF (r = 0.554, P = .003)
xpression. 
xpression of TGF- β cytokines coupled with myofibroblast activation 
Table 3 presents relationships between α-SMA expression, de-
oting myofibroblast activation, and the expression of TGF- β
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Fig 3. Histologic fibrosis correlated positively with hepatic transforming growth factor beta 1 (TGF- β1) and beta 2 (TGF- β2) protein and TGFB1 gene expression after 
median 3.0 years of follow-up. ( A, B ) TGF- β1 and TGF- β2 protein expression correlated positively with METAVIR fibrosis stage. ( C, D ) TGFB1 , but not TGFB2 , gene expression 
correlated positively with METAVIR fibrosis stage. Box plots display the median ( bold transverse line ), interquartile range ( rectangle ), and range. Significance was evaluated 































r  uperfamily cytokines. Protein or RNA expression of all studied TGF
ytokines correlated with α-SMA protein expression, and the RNA
xpression of TGFB2, CTGF, and DCN correlated with ACTA encoding
or α-SMA. 
yndromic BA patients exhibited milder fibrosis and lower expression 
f TGF- β1 than isolated patients 
As presented in Table 4 , histologic variables, age, and protein
xpression of TGF- β1 and 2, CTGF, and decorin were similar be-
ween syndromic and isolated BA patients at PE. In follow-up spec-
mens obtained at a similar age, syndromic patients showed milder
brosis and lower protein expression of TGF- β1 and decorin than
solated patients ( Tables 2 and 4 ). Patients with BASM tended
o have a lower METAVIR fibrosis stage (2 [1–2] versus 3 [2–4],
 = .072) and TGF- β1 protein expression at follow-up (0 [0–1] ver-
us 1 [0–1], P = .205], but the differences did not reach statistical
ignificance. erum TGF- β2 levels were increased in BA patients compared with 
ontrols 
Patients showed increased serum TGF- β2 levels at follow-up
925 [833–1,590] pg/mL) compared with healthy controls (871
599–1,200] pg/mL, P = .016). Serum decorin levels did not differ
etween patients (4,750 [4,090–6,170] pg/mL) and controls (4,630
3,880–5,850] pg/mL), P = .834. 
iscussion 
This is the first study to explore the evolution of hepatic TGF- β
uperfamily cytokine expression after successful PE and resolution
f histologic and biochemical cholestasis. We found that the ex-
ression of TGF- β1 and CTGF—but not that of TGF- β2 or decorin—
ecreased after successful PE. Both the RNA and protein expression
f TGF- β1 correlated with the progression of fibrosis, which was
ore vigorous, along with a higher TGF- β1 expression, in isolated
ather than in syndromic BA patients. These findings suggest that
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Table 3 
Correlation of α-smooth muscle actin protein ( α-SMA area fraction) and gene 
( ACTA fold change) expression with transforming growth factor (TGF) superfamily 
cytokines 
Cytokines α-SMA area fraction n ACTA fold change n 
TGF- β1, grade r = 0.272 24 r = 0.028 23 
P = .179 P = .899 
TGFB1 , fold change r = 0.577 21 r = 0.401 24 
P = .004 P = .052 
TGF- β2, grade r = 0.545 25 r = 0.222 24 
P = .003 P = .298 
TGFB2 , fold change r = 0.496 21 r = 0.663 24 
P = .016 P < .001 
CTGF, grade r = 0.484 25 r = 0.484 23 
P = .011 P = .011 
CTGF , fold change r = 0.427 21 r = 0.650 24 
P = .042 P = .001 
Decorin, grade r = 0.661 22 r = 0.318 21 
P < .001 P = .160 
DCN , fold change r = 0.405 21 r = 0.680 24 
P = .055 P < .001 
TGF- β , transforming growth factor-beta; CTGF , connective tissue growth factor. 
Note: Correlations for immunohistochemical expression (grade) and respective 


























































f  downregulation of hepatic TGF- β1 and CTGF may have a central
role in delaying the progression of liver fibrosis after successful PE.
The TGF- β superfamily forms one of the most potent driving
forces for hepatic fibrogenesis through hepatic stellate cell acti-
vation and epithelial-to-mesenchymal transition. 7,9,26 Three major
isoforms of TGF- β , TGF- β1, TGF- β2, and TGF- β3 show similar
biologic effects in vitro, and their in vivo expression patterns are
very dissimilar from one another. 8,33 TGF- β1 is often described as
the most abundant isoform in hepatic fibrosis. 8,26,34 We found that
hepatic TFG- β1—but not TGF- β2—protein expression decreased
after successful PE, and that TGF- β2 protein and RNA expression,
together with TGF- β3 RNA expression, remained increased in
follow-up specimens. Thus, TFG- β1 expression selectively de-
creased after a successful PE. In addition to a reduced TGF- β1
expression after a successful PE, both protein and RNA expression
of TGF- β1correlated with a progression of histologic fibrosis in
follow-up specimens, providing further support for involvement of
TGF- β1 in the regulation of postoperative fibrogenesis. The mostTable 4 
Differences between syndromic and isolated biliary atre
protein expression and liver histology 
Syndromic BA n 
At portoenterostomy 
age, days 54 (39–77) 12
Metavir stage (0–4) 2 (2–3) 9 
TGF- β1, grade (0–3) 2 (2–2) 9 
TGF- β2, grade (0–2) 1 (1–1) 8 
CTGF, grade (0–3) 2.5 (2–3) 8 
Decorin, grade (0–4) 2.5 (2–3) 6 
At follow-up 
age, years 4.2 (2.0–9.2) 12
Metavir stage (0–4) 2 (1–2) 12
Ductal reaction, (%) ∗ 1.9 (1.5–4.1) 11
TGF- β1, grade (0–3) 0 (0–1) 11
TGFB1 , fold change 1.08 (0.87–1.18) 9 
TGF- β2, grade (0–2) 0.5 (0–1) 12
TGFB2 , fold change 3.49 (2.91–4.25) 9 
TGFB3 , fold change 2.14 (1.64–2.20) 9 
CTGF, grade (0–3) 1 (0–1) 12
CTGF , fold change 1.13 (0.70–2.19) 9 
Decorin, grade (0–4) 2 (1–2) 11
DCN , fold change 1.40 (1.18–1.94) 9 
TGF- β , transforming growth factor-beta; CTGF , connective
∗ Ductal reaction was analyzed using cytokeratin-7 imm
Note: Data are median (interquartile range). Significance ikely and obvious reason for downregulation of TFG- β1 expression
fter a successful PE is the resolution of cholestasis. 35 Interestingly,
n syndromic patients the significant decrease in ductal reaction
ccompanied a lower TFG- β1 expression in relation to isolated
atients. An alternative potential reason for the decreased TGF- β1
xpression after PE may be a reduced TGF- β1–producing capacity
hen fibrosis progresses to cirrhosis and destroys TGF- β–storing
ells. 7,17,19 This seems unlikely because most of our patients were
ot cirrhotic at follow-up, with a median METAVIR stage 2. In
ccordance with our results, earlier studies have described an in-
reased TGF- β1 protein and RNA expression at the time of PE and
gain at LTx, when patients usually have end-stage cirrhosis. 16 , 18–22 
Our findings extend earlier observations by showing that, af-
er a successful PE, liver expression of TGF- β isoforms responded
ivergently to clearance of jaundice, which could be important in
he surveillance and manipulation of postoperative liver fibrosis. In
ontrast with TGF- β1, liver protein and gene expression, and serum
oncentrations of TGF- β2, remained elevated, most likely reflecting
ctive fibrogenesis despite a successful PE. TGF- β2 is usually ex-
ressed by BECs, but in BA also by hepatocytes. 12,15,34,36 We found
GF- β2 expression in hepatocytes and mesenchymal cells in fi-
rotic areas, but in BECs only in 25% of biopsies at follow-up and
one at PE. This might be attributable to a less-advanced stage of
he liver injury in our patients compared with end-stage liver dis-
ase in earlier reports. In line with the increased hepatic expres-
ion, serum TGF- β2 levels were also elevated in BA patients, but
id not correlate with histologic fibrosis. This may be explained by
he fact that the majority of circulating TGF- β is in latent form. 9 
Alterations in the TGF- β expression were accompanied with
vocative changes in other superfamily members. The RNA expres-
ion of TGFBR1 encoding for TGF- β receptor 1 increased compen-
atorily, and SMAD2 promoting intracellular TGF- β signaling was
pregulated. In contrast, the RNA expression of SMAD6 with an in-
ibitory effect on the TGF- β pathway was downregulated in BA
atients compared with nonfibrotic controls. 8,9,33 Decorin has been
eported to inhibit fibrogenesis by binding to TGF- β . 26 Accordingly,
e found increased protein and gene expression of decorin after
uccessful PE, suggesting that upregulation of a decorin expres-
ion may contribute to the deceleration of fibrosis after a success-
ul PE by inhibiting TGF- β–driven fibrogenesis. Similar to TGF- β1,sia (BA) patients in relation to hepatic gene and 
Isolated BA n P value 
 64 (43–90) 16 .430 
2 (2–3) 15 .310 
2 (2–3) 13 .126 
1 (1–1) 15 .210 
2 (2–2) 15 .296 
2 (2–4) 11 1.0 0 0 
 2.9 (2.1–5.2) 16 .642 
 3 (2–4) 16 .019 
 3.1 (1.8–8.6) 16 .167 
 1 (0–1) 16 .015 
0.98 (0.88–1.48) 15 .905 
 1 (0–1) 16 .417 
4.47 (3.01–11.2) 15 .297 
2.01 (1.45–3.77) 15 .929 
 1 (0–1) 15 .411 
0.99 (0.59–1.50) 15 .655 
 2 (2–3) 14 .024 
1.44 (1.18–2.00) 15 .770 
 tissue growth factor. 
unostaining. 
evaluated using Mann-Whitney U test. 













































































































ecorin expression is localized mainly in fibrotic areas and associ-
ted with the histologic fibrosis stage at PE and at follow-up. In our
tudy, the protein expression of CTGF declined, the RNA expression
emained unchanged, and the CTGF protein expression correlated
ith the fibrosis stage, paralleling the findings for TGF- β1. CTGF is
roduced by multiple mesenchymal and epithelial cell types and is
ecognized as a downstream mediator of TGF- β by synergizing its
ctions. 9,23 In other studies, the hepatic CTGF expression has been
ound to be upregulated and to correlate with the degree of fibro-
is at the time of PE. 20,24,25 
In our earlier study, a molecular signature of active fibrogenesis
ersisted after a successful PE, whereas the RNA expression of var-
ous Th1 and Th2 proinflammatory cytokines was low, suggesting
hat inflammation may have a less central role in the progression
f fibrosis after the clearance of jaundice. 32 In the present study,
he coupling of TGF superfamily cytokines with the expression of
-SMA, a marker of extracellular matrix-producing myofibroblast,
trengthens their role as active regulators of native liver fibrogen-
sis after the clearance of jaundice in BA. 
Ductal reaction signifies a typical feature in cholangiopathies,
here hepatocytes or progenitor cells transdifferentiate into CK-7
ositive cell lineages and form immature biliary ductules. 30,37 In
A, the extent of ductular reaction at PE correlates with fibrosis
nd a worse prognosis. 31 We found that the extension of ductu-
ar reaction decreased after PE only in syndromic patients and cor-
elated with fibrosis and the expression of decorin and CTGF at
ollow-up. 
This study had several limitations, such as a relatively small
ample size and various sources of control material, because of the
are incidence of BA and obvious limited availability of control liver
iopsies. In addition, protein or RNA expression of growth factors
oes not necessarily reflect their biological activity. 7,26 However,
his is one of the first studies to explore the TGF- β pathway in
A before the development of liver failure after a successful PE. 
In conclusion, our findings support a central role of the TGF- β
uperfamily in driving liver fibrogenesis after a successful PE. The
elective decline in TGF- β1 and CTGF expression and simultaneous
pregulation of inhibitory decorin may contribute to unprogressive
brogenesis after a successful PE, whereas the expression of TGF-
2 and TFG- β3 may have an opposite effect. Syndromic patients
howed less progressive fibrosis, greater attenuation of ductal reac-
ion, and a lower TGF- β1 expression than isolated ones, strength-
ning the possibility of different etiopathogenesis between these
wo subgroups. These findings may have important clinical impli-
ations for future development of antifibrogenic treatment strate-
ies to delay or even prevent the need for LTx. 
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